Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, [11C]RGH-1756 in the monkey brain

Neurochemistry International

Volumn 45, Issue 5, 2004, Pages 609-617

  Sóvágó, Judit ^a,b   Farde, Lars ^a   Halldin, Christer ^a   Langer, Oliver ^a   Laszlovszky, István ^c   Kiss, Béla ^c   Gulyás, Balázs ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c GEDEON RICHTER LTD   (Hungary)

Author keywords

Dopamine D3 receptor; PET ligand; Positron emission tomography (PET); Primate brain; RGH 1756

Indexed keywords

CARBON 11; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; RACLOPRIDE;

ANIMAL TISSUE; ARTICLE; CEREBELLUM; CORPUS STRIATUM; EMISSION TOMOGRAPHY; HYPOTHESIS; IN VITRO STUDY; LIGAND BINDING; MESENCEPHALON; MONKEY; NEOCORTEX; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BINDING; SCHIZOPHRENIA;

ANIMALS; BIOTRANSFORMATION; BRAIN; DOPAMINE ANTAGONISTS; IMAGE PROCESSING, COMPUTER-ASSISTED; MACACA FASCICULARIS; MALE; PIPERAZINES; PYRIDINES; RACLOPRIDE; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SEROTONIN ANTAGONISTS; THIAZOLES; TOMOGRAPHY, EMISSION-COMPUTED;

MACACA FASCICULARIS; PRIMATES;

EID: 3042681307     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2004.04.004     Document Type: Article

References (37)

1. Bancroft G.N., Morgan K.A., Flietstra R.J., Levant B. Binding of [3H]PD 128907, a putatively selective ligand for the D3 dopamine receptor, in rat brain: a receptor binding and quantitative autoradiographic study. Neuropsychopharmacology. 18:1998;305-316
2. Farde L., Eriksson L., Blomquist G., Halldin C. Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J. Cereb. Blood Flow Metab. 9:1989;696-708
3. Farde L., Ginovart N., Ito H., Lundkvist C., Pike V.W., et al. PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain. Psychopharmacol. Berl. 133:1997;196-202
4. Farde L., Hall H., Ehrin E., Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 231:1986;258-261
5. Ginovart N., Farde L., Halldin C., Swahn C.G. Effect of reserpine-induced depletion of synaptic dopamine on [11C]raclopride binding to D2-dopamine receptors in the monkey brain. Synapse. 25:1997;321-325
6. Gurevich E.V., Bordelon Y., Shapiro R.M., Arnold S.E., Gur R.E., Joyce J.N. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch. Gen. Psychiatry. 54:1997;225-232
7. Hall H., Halldin C., Dijkstra D., Wikstrom H., Wise L.D., et al. Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907. Psychopharmacol. Berl. 128:1996;240-247
8. Halldin C., Farde L., Hogberg T., Hall H., Strom P., et al. A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. Int. J. Rad. Appl. Instrum. B. 18:1991;871-881
9. Halldin C., Farde L., Hogberg T., Mohell N., Hall H., et al. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J. Nucl. Med. 36:1995;1275-1281
10. Joyce J.N. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Synapse. 40:2001;137-144
11. Joyce J.N., Ryoo H.L., Beach T.B., Caviness J.N., Stacy M., et al. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res. 955:2002;138-152
12. Karlsson P., Farde L., Halldin C., Swahn C.G., Sedvall G., et al. PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacol. Berl. 113:1993;149-156
13. Kiss B., Laszlovszky I., Auth F., 2000. Neurochemical characterization of RGH-1756, a potent ligand of dopamine D3 receptors. Presented at XXIInd C.I.N.P. Congress, Bruxelles, Belgium.
14. Langer O., Gulyás B., Sandell J., Laszlovszky I., Kiss B., et al. Radiochemical labelling of the dopamine D3 receptor ligand RGH-1756. J. Labelled Cpd. Radiopharm. 43:2000;1069-1074
15. Laszlovszky I., Acs T., Kiss B., Domany G. Substituted phenoxyalkylpiperazines as dopamine D3 receptor ligands. Pharmazie. 56:2001;287-289
16. Laszlovszky I., Kiss B., Csejtei M., Kovács K.J., Auth F., et al., 2000. Neurochemical and behavioural properties of RGH-1756 a D3 dopamine receptor ligand. Presented at Society of Neuroscience.
17. Leriche L., Schwartz J.C., Sokoloff P. The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology. 45:2003;174-181
18. Levant B. Differential sensitivity of [3H]7-OH-DPAT-labeled binding sites in rat brain to inactivation by N-ethoxycarbonyl-2-ethoxy-12-dihydroquinoline. Brain Res. 698:1995;146-154
19. Levant B. Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res. 800:1998;269-274
20. Levesque D., Diaz J., Pilon C., Martres M.P., Giros B., et al. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N, N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. U.S.A. 89:1992;8155-8159
21. Malmberg, M., Mohell, N., 1998. Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'-gamma-thio-triphosphate-35S- binding. J. Pharmacol. Exp. Ther. 285, 119-126.
22. Murray A.M., Ryoo H.L., Gurevich E., Joyce J.N. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc. Natl. Acad. Sci. U.S.A. 91:1994;11271-11275
23. Paxinos, G.H.X.-F., Toga, A.-W., 2000. The Rhesus Monkey Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA.
24. Pugsley T.A., Davis M.D., Akunne H.C., MacKenzie R.G., Shih Y.H., et al. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J. Pharmacol. Exp. Ther. 275:1995;1355-1366
25. Ricci A., Vega J.A., Mammola C.L., Amenta F. Localisation of dopamine D3 receptor in the rat cerebellar cortex: a light microscope autoradiographic study. Neurosci. Lett. 190:1995;163-166
26. Roland P.E., Graufelds C.J., Wåhlin J., Ingeman L., Andersson M., et al. Human brain atlas: for high-resolution functional and anatomical mapping. Hum. Brain. Map. 1:1994;173-184
27. Ryoo H.L., Pierrotti D., Joyce J.N. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord. 13:1998;788-797
28. Schotte A., Janssen P.F., Bonaventure P., Leysen J.E. Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study. Histochem. J. 28:1996;791-799
29. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Leysen J.E. Autoradiographic evidence for the occlusion of rat brain dopamine D3 receptors in vivo. Eur. J. Pharmacol. 218:1992;373-375
30. Schwartz J.C., Diaz J., Pilon C., Sokoloff P. Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res. Brain Res. Rev. 31:2000;277-287
31. Sokoloff P., Andrieux M., Besancon R., Pilon C., Martres M.P., et al. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur. J. Pharmacol. 225:1992;331-337
32. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 347:1990;146-151
33. Stanwood G.D., Artymyshyn R.P., Kung M.P., Kung H.F., Lucki I., McGonigle P. Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [(125)I]7-OH-PIPAT: evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J. Pharmacol. Exp. Ther. 295:2000a;1223-1231
34. Stanwood G.D., Lucki I., McGonigle P. Differential regulation of dopamine D2 and D3 receptors by chronic drug treatments. J. Pharmacol. Exp. Ther. 295:2000b;1232-1240
35. Vanhauwe J.F., Ercken M., van de Wiel D., Jurzak M., Leysen J.E. Effects of recent and reference antipsychotic agents at human dopamine D2 and D3 receptor signaling in Chinese hamster ovary cells. Psychopharmacol. Berl. 150:2000;383-390
36. Vizi E.S. Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol. Rev. 52:2000;63-89
37. Wienhard K., Dahlbom M., Eriksson L., Michel C., Bruckbauer T., et al. The ECAT EXACT HR: performance of a new high resolution positron scanner. J. Comput. Assist. Tomogr. 18:1994;110-118